BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 33590608)

  • 21. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.
    Piroth L; Wittkop L; Lacombe K; Rosenthal E; Gilbert C; Miailhes P; Carrieri P; Chas J; Poizot-Martin I; Gervais A; Dominguez S; Neau D; Zucman D; Billaud E; Morlat P; Aumaitre H; Lascoux-Combe C; Simon A; Bouchaud O; Teicher E; Bani-Sadr F; Alric L; Vittecoq D; Boué F; Duvivier C; Valantin MA; Esterle L; Dabis F; Sogni P; Salmon D;
    J Hepatol; 2017 Jul; 67(1):23-31. PubMed ID: 28235612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long.
    Brouard C; Pillonel J; Boussac M; de Lédinghen V; Rachas A; Silvain C; Lydié N; Chevaliez S; Pioche C; Durand J; Lot F; Delarocque-Astagneau E
    BMC Infect Dis; 2020 Oct; 20(1):759. PubMed ID: 33059617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan.
    Chen CY; Huang CF; Cheng PN; Tseng KC; Lo CC; Kuo HT; Huang YH; Tai CM; Peng CY; Bair MJ; Chen CH; Yeh ML; Lin CL; Lin CY; Lee PL; Chong LW; Hung CH; Huang JF; Yang CC; Hu JT; Lin CW; Chen CT; Wang CC; Su WW; Hsieh TY; Lin CL; Tsai WL; Lee TH; Chen GY; Wang SJ; Chang CC; Mo LR; Yang SS; Wu WC; Huang CS; Hsiung CK; Kao CN; Tsai PC; Liu CH; Lee MH; Liu CJ; Dai CY; Kao JH; Chuang WL; Lin HC; Yu ML
    Liver Int; 2021 Jun; 41(6):1265-1277. PubMed ID: 33655714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
    J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam.
    Nguyen DT; Tran TTT; Nghiem NM; Le PT; Vo QM; Day J; Rahman M; Le HM
    PLoS One; 2020; 15(5):e0233446. PubMed ID: 32433676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review.
    Greenaway C; Makarenko I; Chakra CNA; Alabdulkarim B; Christensen R; Palayew A; Tran A; Staub L; Pareek M; Meerpohl JJ; Noori T; Veldhuijzen I; Pottie K; Castelli F; Morton RL
    Int J Environ Res Public Health; 2018 Sep; 15(9):. PubMed ID: 30223539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer in People with and without Hepatitis C Virus Infection: Comparison of Risk Before and After Introduction of Direct-Acting Antivirals.
    Lam JO; Hurley LB; Lai JB; Saxena V; Seo S; Chamberland S; Quesenberry CP; Champsi JH; Ready J; Chiao EY; Marcus JL; Silverberg MJ
    Cancer Epidemiol Biomarkers Prev; 2021 Dec; 30(12):2188-2196. PubMed ID: 34583968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.
    ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Electronic address: stanislas.pol@aphp.fr
    J Hepatol; 2016 Oct; 65(4):734-740. PubMed ID: 27288051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world treatment outcome of direct-acting antivirals and patient survival rates in chronic hepatitis C virus infection in Eritrea.
    Ghebremeskel GG; Berhe Solomon M; Achila OO; Mengistu ST; Asmelash RF; Berhane Mesfin A; Hamida ME
    Sci Rep; 2023 Nov; 13(1):20792. PubMed ID: 38012181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic diversity of genotype 6 HCV infections in France: Epidemiology and consequences for treatment strategy.
    Pronier C; Fontaine H; Dorival C; Carrat F; Pol S; Thibault V;
    J Viral Hepat; 2019 Nov; 26(11):1276-1283. PubMed ID: 31273896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
    Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ;
    Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):533-546. PubMed ID: 33965006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
    Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
    J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators.
    Serumondo J; Penkunas MJ; Niyikora J; Ngwije A; Kiromera A; Musabeyezu E; Umutesi J; Umuraza S; Musengimana G; Nsanzimana S
    BMC Public Health; 2020 Jun; 20(1):946. PubMed ID: 32546216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients.
    Yaya I; Roux P; Marcellin F; Wittkop L; Esterle L; Spire B; Dominguez S; Elegbe BA; Piroth L; Sogni P; Salmon-Ceron D; Carrieri MP;
    PLoS One; 2018; 13(7):e0199874. PubMed ID: 29975764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland.
    Bachofner J; Valli PV; Bergamin I; Kröger A; Künzler P; Baserga A; Braun DL; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens J; The Swiss Hepatitis C Cohort Study
    Swiss Med Wkly; 2018; 148():w14560. PubMed ID: 29376557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
    Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
    J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study.
    Chen Q; Ayer T; Bethea E; Kanwal F; Wang X; Roberts M; Zhuo Y; Fagiuoli S; Petersen J; Chhatwal J
    BMJ Open; 2019 Jun; 9(6):e026726. PubMed ID: 31189677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C.
    Ramsay J; Marsh J; Pedrana A; Andric N; Norman R; Cheng W; Webb S; Zeps N; Bellgard M; Graves T; Hellard M; Snelling T
    BMC Infect Dis; 2020 Oct; 20(1):802. PubMed ID: 33121439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals.
    Serper M; Evon DM; Stewart PW; Lok AS; Amador J; Reeve BB; Golin CE; Fried MW; Reddy KR; Sterling RK; Sarkar S; Di Bisceglie AM; Lim JK; Nelson DR; Reau N
    J Gen Intern Med; 2020 Apr; 35(4):1011-1020. PubMed ID: 31659661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.